PD Dr. Markus Eckstein

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Institute of Pathology

Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (2019) Weyerer V, Weisser R, Moskalev E, Haller F, Stöhr R, Eckstein M, Zinnall U, et al. Journal article Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial) (2019) Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Hautmann MG, et al. Conference contribution Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods (2019) Weyerer V, Stöhr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (2019) Weyerer V, Weisser R, Moskalev E, Haller F, Stoehr R, Eckstein M, Zinnall U, et al. Journal article Large nested variant of urothelial carcinoma: a prime example of a FGFR3-mutated, luminal tumour (2019) Weyerer V, Eckstein M, Comperat E, Juette H, Allory Y, Stoehr R, Wullich B, et al. Conference contribution Tumour immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes (2019) Eckstein M, Strissel P, Pfannstiel C, Chiappinelli K, Sikic D, Wach S, Taubert H, et al. Conference contribution Analytical and inter-observer comparability of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry assays in advanced clear cell renal cell carcinoma (CCRCC) (2019) Sommer U, Eckstein M, Ammann J, Braunschweig T, Macher-Goeppinger S, Schwamborn K, Hieke-Schulz S, et al. Conference contribution